Table 2.

Differences in the synaptic proteins Rab3A, SNAP25 and neurogranin assessed by ELISA

	Control (N = 87)	Total PD (N = 52)		Drug naive PD (N = 30)		Treated PD (N = 22)
Rab3A (pg/mL)	124 ± 4.8 (65–352)	125 ± 6.5 (66–365)	p = .765	124 ± 9.3 (66–314)	p = .831	127 ± 8.8 (102–365)	p = .642
SNAP25 (pg/mL)	160 ± 7.6 (56–258)	184 ± 9.9 (57–302)	p = .033	167 ± 12.7 (57–302)	p = .488	205 ± 15.1 (74–213)	p = .005
Neurogranin (pg/mL)	338 ± 7.4 (208–518)	359 ± 7.9 (234–487)	p = .057	367 ± 9.95 (275–439)	p = .023	347 ± 13.1 (234–487)	p = .571

CSF concentrations of presynaptic protein SNAP25 are increased in total PD and in treated PD patient group CSF concentration of neurogranin is significantly increased only in the drug naïve group of PD patients while CSF concentration of Rab3A remains unaffected in PD. Concentrations are expressed in pg/mL (means ± standard deviation, with minimum and maximum values in parenthesis).

p values represent statistical differences using Mann-Whitney U test resulting from comparisons of PD cases to non-demented control groups.